Behrman Capital Invests in The Emmes Corporation
March 11, 2019
Behrman Capital, a private equity firm, made a significant investment in The Emmes Corporation, a Rockville, Maryland–based contract research organization (CRO). Management will remain in place and Sal Guccione joined as Executive Chairman; Behrman said the investment will support growth—including expanding non‑government business, global presence, and accretive acquisitions.
- Buyers
- Behrman Capital
- Targets
- The Emmes Corporation
- Industry
- Healthcare Services
- Location
- Maryland, United States
- Transaction Type
- Recapitalization
Explore More
Related Acquisitions
-
New Mountain Capital Acquires Emmes from Behrman Capital
June 21, 2022
Healthcare Services
Affiliates of New Mountain Capital have agreed to acquire Emmes, a global clinical research organization, from Behrman Capital and Emmes' other investors. The transaction, expected to close in early July 2022, positions Emmes for its next phase of growth with additional investment to expand its commercial, global and eClinical technology capabilities; terms were not disclosed.
-
Emmes Acquires Essex Management
March 21, 2023
Healthcare Services
Emmes, a global full-service clinical research organization, acquired Essex Management, a bioinformatics and health information technology consultancy, to enhance Emmes' data, bioinformatics and HIT capabilities. The acquisition adds more than 100 employees and expands Emmes' ability to serve government, academic and biopharma clients, including continued support for the National Cancer Institute.
-
Emmes Acquires Neox
December 30, 2020
Healthcare Services
The Emmes Company, a Behrman Capital portfolio company, has acquired Prague-headquartered CRO Neox S.R.O., an add-on that expands Emmes' BioPharma capabilities and Central/Eastern European presence. Financial terms were not disclosed; Neox brings over 150 employees and operations across multiple European countries, and founders Pavel and Petr Marek will remain in leadership roles.
-
Emmes Acquires UK-Based Orphan Reach
May 11, 2021
Healthcare Services
Emmes, a global full-service CRO and portfolio company of Behrman Capital, acquired Orphan Reach, a UK-based CRO specialized in rare-disease clinical research. The add-on expands Emmes' geographic footprint and rare-disease capabilities; Orphan Reach's founder and management will remain in place and financial terms were not disclosed.
-
Emmes Acquires Casimir to Strengthen Rare Disease Research Capabilities
May 10, 2022
Healthcare Services
Emmes, a portfolio company of Behrman Capital, has acquired Casimir, a Plymouth, Massachusetts–based CRO specializing in rare disease outcome measures and virtual/remote assessments. The add-on expands Emmes' rare disease center of excellence and brings Casimir's clinical outcomes technology and expertise into Emmes' global service offerings; terms were not disclosed.
-
Kester Capital Acquires EMAS Pharma (carve-out from Bionical Emas)
December 24, 2024
Healthcare Services
Kester Capital has acquired EMAS Pharma, the clinical development division of Bionical Emas, in a carve-out transaction alongside an incoming executive team led by experienced CRO operators. The deal creates an independent CRO platform that Kester and the management team intend to scale organically and through acquisitions, expanding capabilities and geographic presence in North America and Europe.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.